Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura

Acta Pharmacologica Sinica

Volumn 26, Issue 5, 2005, Pages 598-602

  Zhang, Wang Gang ^a   Ji, Lei ^a   Cao, Xing Mei ^a   Chen, Yin Xia ^a   He, Ai Li ^a   Liu, Jie ^a   Zhao, Wan Hong ^a   Zou, San Peng ^a  

^a THE SECOND AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Apoptosis; Female; Idiopathic thrombocytopenic purpura; Male; Mycophenolate acid

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHINESE DRUG; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DANAZOL; IMMUNOGLOBULIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THROMBOCYTE ANTIBODY; VINCRISTINE;

ABDOMINAL DISTENSION; ADOLESCENT; ADULT; AGED; ANOREXIA; ARTICLE; CELL ISOLATION; CHINA; CHINESE MEDICINE; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENDER; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN BLOOD LEVEL; MALE; NAUSEA; NICK END LABELING; PERIPHERAL BLOOD MONONUCLEAR CELL; SCHOOL CHILD; SEX DIFFERENCE; SPLENECTOMY; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BLOOD PLATELETS; CD4-CD8 RATIO; CHILD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECURRENCE; SEX FACTORS;

EID: 18744397878     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2005.00088.x     Document Type: Article

References (15)

1. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346: 995-1008.
2. Bussel JB. Novel approaches to refractory immune thrombocytopenic purpura. Blood Rev 2002; 16: 31-6.
3. Becker BN. Mycophenolate mofetil. Transplant Proc 1999; 31: 2777-8.
4. Glander P, Hambach P, Braun KP, Fritsche L, Waiser J, Mai I, et al. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. Int J Clin Pharmacol Ther 2003; 41: 470-6.
5. Gellermann J, Querfeld U. Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil. Pediatr Nephrol 2004; 19: 101-4.
6. Wenzl HH, Hinterleitner TA, Aichbichler BW, Fickert P, Petritsch W. Mycophenolate mofetil for Crohn's disease: short-term efficacy and long-term outcome. Aliment Pharmacol Ther 2004; 19: 427-34.
7. Srinivas TR, Kaplan B, Meier-Kriesche HU. Mycophenolate mofetil in solid-organ transplantation. Expert Opin Pharmacother 2003; 4: 2325-45.
8. Cines DB, McKenzie SE, Siegel DL. Mechanisms of action of therapeutics in idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2003; 25 Suppl 1: S52-6.
9. Narang M, Penner JA, Williams D. Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab). Am J Hematol 2003; 74: 263-7.
10. Howard J, Hofferand AV, Prentice HG, Mehta A. Mycophenolate mofetil for the treatment of refractory auto immune haemolytic anemia and auto immune thrombocytopenia purpura. Br J Haematol 2002; 117: 712-5.
11. Kneitz C, Wilhelm M, Tony HP. Effective B cell depletion with rituximab in the treatment of autoimmune disease. Immunobiology 2002; 206: 519-27.
12. Hou M, Peng J, Shi Y, Zhang C, Qin P, Zhao C, et al. Mycophenolate mofetil for the treatment of steroid resistant idiopathic thrombocytopenic purpura. Eur J Hematol 2003; 70: 353-7.
13. Goldsmith D, Carrey EA, Edbury S, Smolenski RT, Jagodzinski P, Simmonds HA. Mycophenolate mofetil, an inhibitor of IMP dehydrogenase, causes paradoxical elevation of GTP in erythrocytes of renal transplant patients. Clin Sci (Lond) 2004; 107: 63-8.
14. Cohn RG, Mirkovich A. Mycophenolic acid increases apoptosis lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation 1999; 68: 411-8.
15. Padalko E, Verbeken E, Matthys P, Aerts JL, Clercq ED, Neyts J. Mycophenolate mofetil inhibits the development of Coxsackie B3-virus-induced myocarditis in mice. BMC Microbiol 2003; 3: 25-8.